Abstract
The role of vitamin D (VitD) has recently been expanded beyond bone homeostasis and regulation of calcium levels. VitD deficiency has been proposed as a new risk factor for cardiovascular disease, including stroke. Low 25(OH)VitD levels are very common among post-stroke patients, probably due to their limited mobility and decreased sunlight exposure along with a higher prevalence of malnutrition, and they have been associated with previous and incident cerebrovascular events. Contributing mechanisms have been linked to the association of VitD deficiency with the presence of hypertension, diabetes mellitus and atherosclerosis. Moreover, there is experimental evidence demonstrating that VitD exerts neuroprotective effects, such as stimulation of neurotrophic factors, quenching of oxidative hyperactivity and regulation of neuronal death, as well as antithrombotic properties. It is plausible that VitD supplementation could be a beneficial intervention for the prevention and/or treatment of cerebrovascular disease possibly by decreasing the aforementioned cerebrovascular risk factors and simultaneously by improving neurologic and cognitive functions, thereby reducing falls and fractures in post-stroke patients. However, study results are still conflicting and data from large, randomized clinical trials are needed to clarify these speculations.
Keywords: Antiatherogenic effect, antithrombotic effect, cardiovascular disease, deficiency, neuroprotection, stroke, vitamin D.
Current Vascular Pharmacology
Title:Vitamin D and Stroke: Promise for Prevention and Better Outcome
Volume: 12 Issue: 1
Author(s): Stefania E. Makariou, Patrik Michel, Meropi S. Tzoufi, Anna Challa and Haralampos J. Milionis
Affiliation:
Keywords: Antiatherogenic effect, antithrombotic effect, cardiovascular disease, deficiency, neuroprotection, stroke, vitamin D.
Abstract: The role of vitamin D (VitD) has recently been expanded beyond bone homeostasis and regulation of calcium levels. VitD deficiency has been proposed as a new risk factor for cardiovascular disease, including stroke. Low 25(OH)VitD levels are very common among post-stroke patients, probably due to their limited mobility and decreased sunlight exposure along with a higher prevalence of malnutrition, and they have been associated with previous and incident cerebrovascular events. Contributing mechanisms have been linked to the association of VitD deficiency with the presence of hypertension, diabetes mellitus and atherosclerosis. Moreover, there is experimental evidence demonstrating that VitD exerts neuroprotective effects, such as stimulation of neurotrophic factors, quenching of oxidative hyperactivity and regulation of neuronal death, as well as antithrombotic properties. It is plausible that VitD supplementation could be a beneficial intervention for the prevention and/or treatment of cerebrovascular disease possibly by decreasing the aforementioned cerebrovascular risk factors and simultaneously by improving neurologic and cognitive functions, thereby reducing falls and fractures in post-stroke patients. However, study results are still conflicting and data from large, randomized clinical trials are needed to clarify these speculations.
Export Options
About this article
Cite this article as:
Makariou E. Stefania, Michel Patrik, Tzoufi S. Meropi, Challa Anna and Milionis J. Haralampos, Vitamin D and Stroke: Promise for Prevention and Better Outcome, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/15701611113119990119
DOI https://dx.doi.org/10.2174/15701611113119990119 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
<i>Rhizoma Coptidis</i> for Alzheimer’s Disease and Vascular Dementia: A Literature Review
Current Vascular Pharmacology Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Hypertension in Obstructive Sleep Apnoea
Vascular Disease Prevention (Discontinued) What is the Real Efficacy of Beta-Blockers for the Treatment of Essential Hypertension?
Current Pharmaceutical Design Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of White Matter Abnormalities in Treatment-Resistant Depression: A Systematic Review
Current Pharmaceutical Design Understanding Heterogeneity in Supplementation Effects of Selenium in Men: A Study of Stratification Variables and Human Genetics in a Prospective Sample from New Zealand
Current Pharmacogenomics and Personalized Medicine Podocytes as a Target of Insulin
Current Diabetes Reviews Inhibition of the Calcineurin-NFAT Signalling Cascade in the Treatment of Heart Failure
Recent Patents on Cardiovascular Drug Discovery On Sports And Genes
Recent Patents on DNA & Gene Sequences Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Current Drug Safety Dosing of Antibiotics in Critically Ill Patients Undergoing Renal Replacement Therapy
Current Pharmaceutical Biotechnology Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
Current Pharmaceutical Design Protease-Activated Receptor-2 Antagonists and Agonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Application of Bioinformatics in Search for Cleavable Peptides of SARSCoV Mpro and Chemical Modification of Octapeptides
Medicinal Chemistry Current Developments in the Therapeutic Potential of S-Nitrosoglutathione, an Endogenous NO-Donor Molecule
Current Pharmaceutical Biotechnology The Breath of Life: Recent Patents on Placental and Amnion Derived Cells for Treatment of Bronchopulmonary Dysplasia
Recent Patents on Regenerative Medicine Influence of Hypertension, Alone and in Combination with Other Vascular Risk Factors on Cognition
CNS & Neurological Disorders - Drug Targets The Lipid-lowering Effects and Associated Mechanisms of Dietary Phytosterol Supplementation
Current Pharmaceutical Design